A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
(February 2, 2016), "Forensic Chemistry and Ambient Mass Spectrometry: A Perfect Couple Destined for a Happy Marriage?", Analytical Chemistry, 88 (5), American Chemical Society (ACS): 2515–2526, doi:10.1021/acs.analchem.5b02397, ISSN 0003-2700, PMID 26768158 Wu, Chunping; Dill, Allison L.; Eberlin, Livia S.; Cooks, R. Graham; Ifa, Demian R. (September 20, 2012), "Mass spectrometry imaging under ambient conditions", Mass Spectrometry Reviews, 32 (3), Wiley: 218–243, doi:10.1002/mas.21360, ISSN 0277-7037, PMC 3530640, PMID 22996621 Eberlin, Livia S.; Norton, Isaiah; Orringer, Daniel; Dunn, Ian F.; Liu, Xiaohui; Ide, Jennifer L.; Jarmusch, Alan K.; Ligon, Keith L.; Jolesz, Ferenc A.; Golby, Alexandra J.; Santagata, Sandro; Agar, Nathalie Y. R.; Cooks, R. Graham (January 8, 2013), "Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors", Proceedings of the National Academy of Sciences, 110 (5): 1611–1616, Bibcode:2013PNAS..110.1611E, doi:10.1073/pnas.1215687110, ISSN 0027-8424, PMC 3562800, PMID 23300285 Eberlin, Livia S.; Norton, Isaiah; Dill, Allison L.; Golby, Alexandra J.; Ligon, Keith L.; Santagata, Sandro; Cooks, R. Graham; Agar, Nathalie Y.R. (January 31, 2012), "Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry", Cancer Research, 72 (3), American Association for Cancer Research (AACR): 645–654, doi:10.1158/0008-5472.can-11-2465, ISSN 0008-5472, PMC 3271168, PMID 22139378
The antiandrogenic activity of CPA is dose-dependent. Although CPA is a potent antiandrogen, relatively high doses of CPA are nonetheless required for clinically important AR antagonism. The clinical antiandrogenic efficacy of birth control pills containing CPA, which have only low doses of CPA in them (2 mg/day), often can't be distinguished from that of birth control pills containing other progestins. It is likely that the antiandrogenic effects of CPA-containing birth control pills are due mostly to the ethinylestradiol component and/or suppression of androgen levels, rather than the antiandrogenic activity of the small doses of CPA present in them. CPA has been found to decrease inflammatory acne lesions in males by about 15% at 5 mg/day, by 45% at 25 mg/day, and by 73% at 100 mg/day. A dosage of 100 mg/day CPA can achieve a 65 to 70% reduction in sebum excretion rate in males within 4 weeks of treatment, but doses of 10 mg/day CPA or less are said to have a negligible effect. On the basis of these findings, it has estimated that the threshold dosage of CPA to reduce sebum production may be 5 mg/day in males. In other studies, 25 mg/day CPA resulted in substantial improvement or complete clearance of severe acne in almost all males, whereas 12.5 mg/day was ineffective. CPA has been found to be strongly catabolic in young healthy males. It was shown to result in a mean negative nitrogen balance of 1.2 g at 50 mg/day, 1.4 g at 100 mg/day, and 2.5 g at 200 mg/day. This corresponded to mean losses of lean tissue of 780, 945, and 1,515 g, respectively.
Later that summer, as donations declined sharply in the wake of Bakker's resignation and the end of The PTL Club, Falwell raised $20 million to keep Heritage USA solvent and took a promised water slide ride at the park. Falwell and the remaining members of the PTL board resigned in October 1987, stating that a ruling from a bankruptcy court judge made rebuilding the ministry impossible. In response to the scandal, Falwell called Bakker a liar, an embezzler, a sexual deviant, and "the greatest scab and cancer on the face of Christianity in 2,000 years of church history". On CNN, Swaggart stated that Bakker was a "cancer in the body of Christ". In February 1988, Swaggart became involved in a sex scandal of his own after being caught visiting prostitutes in New Orleans. The Bakker and Swaggart scandals had a profound effect on the world of televangelism, causing greater media scrutiny of TV ministers and their finances. Falwell said that the scandals had "strengthened broadcast evangelism and made Christianity stronger, more mature and more committed."
Upon addition of surfactants or inorganic salts to a droplet-based microfluidic system, the interfacial tension of individual droplets alters within the microfluidic system. These separatory components allow for the utilization of the droplets as microreactors for various procedural mechanisms. In order to describe the relationship between interfacial tension (), concentration of dissociated surfactants/salts in the bulk droplet (C), Temperature (T), the Boltzmann constant (kB), and the concentration of dissociated surfactants/salts at the interface (Γ), the Gibbs adsorption isotherm was created, a simplified section highlighting relevant information displayed to the right. This isotherm reaffirms the notion that while the inorganic salt concentration increases, salts are depleted from the droplet interface (Γ<0), and the interface tension of the droplet increases. This is contrasted by surfactants, which adsorb at the interface (Γ>0), and lower interfacial tension . At low surfactant concentrations, surface tension decreases according to the Gibbs adsorption isotherm, until a certain concentration is reached, known as the critical micelle concentration (CMC), when micelles begin to form. Upon reaching the CMC, the dissolved surfactant concentration reaches a maximum, where the surfactant monomers will aggregate to form nanometer sized micelles. Due to this potential for micelle formation, three steps can be utilized when analyzing the adsorption of the surfactants to the droplet's interface.
Very low voltages are inefficient since the lead wires would conduct too much heat away from the filament, so the practical lower limit for incandescent lamps is 1.5 volts. Very long filaments for high voltages are fragile, and lamp bases become more difficult to insulate, so lamps for illumination are not made with rated voltages over 300 volts. Some infrared heating elements are made for higher voltages, but these use tubular bulbs with widely separated terminals.
Sources: en.wikipedia.org
Caridad del Rosario Diego Bello, the head of the Office of Religious Affairs, then held a private meeting with a group of Freemasons. She told them that she had no knowledge about anything that had been happening, but encouraged everyone to abide by the Ministry of Justice so that the fraternity could continue to operate in Cuba.
==== Impact of phonation ==== The viscoelastic properties of human vocal fold lamina propria are essential for their vibration, and depend on the composition and structure of their extracellular matrix. Adult vocal cords have a layered structure which is based on the layers differential in extracellular matrix distribution. Newborns on the other hand, do not have this layered structure. Their vocal cords are uniform, and immature, making their viscoelastic properties most likely unsuitable for phonation. Hyaluronic acid plays a very important role in the vocal fold biomechanics. In fact, hyaluronic acid has been described as the extracellular matrix molecule that not only contributes to the maintenance of an optimal tissue viscosity that allows phonation, but also of an optimal tissue stiffness that allows frequency control. CD44 is a cell surface receptor for HA. Cells such as fibroblasts are responsible for synthesizing extracellular matrix molecules. Cell surface matrix receptors in return, feed back to the cells through cell-matrix interaction, allowing the cell to regulate its metabolism. Sato et al. carried out a histopathologic investigation of unphonated human vocal cords. Vocal fold mucosae, which were unphonated since birth, of three young adults (17, 24, and 28 years old) were looked at using light and electron microscopy. The results show that the vocal fold mucosae were hypoplastic, and rudimentary, and like newborns, did not have any vocal ligament, Reinke's space, or layered structure. Like newborns, the lamina propria appeared as a uniform structure.
=== Aviation === In 2023, Transworld Group expanded into the aviation sector with its luxury private jet charter service, Airavat, operating in the Middle East, Europe, and Asia. In 2024, Transworld Group entered into a joint venture with former SpiceJet COO Arun Kashyap's Sirius India Airlines to begin operations in India.
On 15 January 2022, the murder of Ebrahim Buzhu took place in Chiclana de la Frontera, Spain. Buzhu, a Dutch drug trafficker of Moroccan origin, was shot through the head and his body was found by a passerby who had notified the Civil Guard. The rented vehicle of Ebrahim Buzhu, next to the body, had been lit on fire. Following an investigation, the Spanish police concluded that Buzhu had been kidnapped and severely tortured, prior to being murdered.
Back pain can also be referred from another source. Referred pain occurs when pain is felt at a location different than the source of the pain. Disease processes that can present with back pain include pancreatitis, kidney stones, severe urinary tract infections and abdominal aortic aneurysms.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.